AU2021103347A4 - Method for recognizing peripheral blood circulating tumor cell of tumor patient based on isolation by size of epithelial tumor cells - Google Patents
Method for recognizing peripheral blood circulating tumor cell of tumor patient based on isolation by size of epithelial tumor cells Download PDFInfo
- Publication number
- AU2021103347A4 AU2021103347A4 AU2021103347A AU2021103347A AU2021103347A4 AU 2021103347 A4 AU2021103347 A4 AU 2021103347A4 AU 2021103347 A AU2021103347 A AU 2021103347A AU 2021103347 A AU2021103347 A AU 2021103347A AU 2021103347 A4 AU2021103347 A4 AU 2021103347A4
- Authority
- AU
- Australia
- Prior art keywords
- ctc
- peripheral blood
- conducting
- cell
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 title claims abstract description 90
- 210000005259 peripheral blood Anatomy 0.000 title claims abstract description 38
- 239000011886 peripheral blood Substances 0.000 title claims abstract description 38
- 238000000034 method Methods 0.000 title claims abstract description 27
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 17
- 210000004881 tumor cell Anatomy 0.000 title claims abstract description 16
- 238000002955 isolation Methods 0.000 title claims abstract description 8
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 claims abstract description 33
- 210000004027 cell Anatomy 0.000 claims abstract description 29
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims abstract description 28
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims abstract description 26
- 210000002889 endothelial cell Anatomy 0.000 claims abstract description 11
- 230000000984 immunochemical effect Effects 0.000 claims abstract description 8
- 210000000265 leukocyte Anatomy 0.000 claims abstract description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 31
- 239000012528 membrane Substances 0.000 claims description 21
- 239000000243 solution Substances 0.000 claims description 17
- 241000282414 Homo sapiens Species 0.000 claims description 15
- 238000011534 incubation Methods 0.000 claims description 14
- 239000012192 staining solution Substances 0.000 claims description 14
- 238000005374 membrane filtration Methods 0.000 claims description 13
- 238000010186 staining Methods 0.000 claims description 13
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 claims description 12
- 210000004369 blood Anatomy 0.000 claims description 12
- 239000008280 blood Substances 0.000 claims description 12
- 238000005406 washing Methods 0.000 claims description 11
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical group C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 claims description 10
- 238000001914 filtration Methods 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 238000004042 decolorization Methods 0.000 claims description 7
- 230000014509 gene expression Effects 0.000 claims description 7
- 230000003287 optical effect Effects 0.000 claims description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
- 239000011521 glass Substances 0.000 claims description 6
- 239000003085 diluting agent Substances 0.000 claims description 5
- 238000005516 engineering process Methods 0.000 claims description 5
- 238000010790 dilution Methods 0.000 claims description 4
- 239000012895 dilution Substances 0.000 claims description 4
- 239000003550 marker Substances 0.000 claims description 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims description 3
- 241000283707 Capra Species 0.000 claims description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 3
- 229930040373 Paraformaldehyde Natural products 0.000 claims description 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 3
- 229920004890 Triton X-100 Polymers 0.000 claims description 3
- 239000013504 Triton X-100 Substances 0.000 claims description 3
- 238000007605 air drying Methods 0.000 claims description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 3
- 229920001400 block copolymer Polymers 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 230000018044 dehydration Effects 0.000 claims description 3
- 238000006297 dehydration reaction Methods 0.000 claims description 3
- 230000004069 differentiation Effects 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- 230000005484 gravity Effects 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 230000007935 neutral effect Effects 0.000 claims description 3
- 229920002866 paraformaldehyde Polymers 0.000 claims description 3
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 claims description 3
- 239000011347 resin Substances 0.000 claims description 3
- 229920005989 resin Polymers 0.000 claims description 3
- 238000007789 sealing Methods 0.000 claims description 3
- 239000008399 tap water Substances 0.000 claims description 3
- 235000020679 tap water Nutrition 0.000 claims description 3
- 210000003462 vein Anatomy 0.000 claims description 3
- 239000008096 xylene Substances 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 2
- 238000002791 soaking Methods 0.000 claims description 2
- 230000002055 immunohistochemical effect Effects 0.000 claims 4
- 238000002360 preparation method Methods 0.000 claims 1
- 238000001514 detection method Methods 0.000 description 16
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 10
- 239000007788 liquid Substances 0.000 description 6
- 239000002699 waste material Substances 0.000 description 6
- 210000000601 blood cell Anatomy 0.000 description 5
- 229910052742 iron Inorganic materials 0.000 description 5
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 210000001772 blood platelet Anatomy 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000012760 immunocytochemical staining Methods 0.000 description 3
- 238000003364 immunohistochemistry Methods 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 201000007270 liver cancer Diseases 0.000 description 3
- 208000014018 liver neoplasm Diseases 0.000 description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- 108010013709 Leukocyte Common Antigens Proteins 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 208000013210 hematogenous Diseases 0.000 description 2
- 201000010982 kidney cancer Diseases 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 201000003076 Angiosarcoma Diseases 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 108010069381 Platelet Endothelial Cell Adhesion Molecule-1 Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 238000010817 Wright-Giemsa staining Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 201000011066 hemangioma Diseases 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000012151 immunohistochemical method Methods 0.000 description 1
- 238000011528 liquid biopsy Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000001578 tight junction Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/30—Staining; Impregnating ; Fixation; Dehydration; Multistep processes for preparing samples of tissue, cell or nucleic acid material and the like for analysis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/40—Concentrating samples
- G01N1/4077—Concentrating samples by other techniques involving separation of suspended solids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/49—Blood
- G01N33/491—Blood by separating the blood components
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/40—Concentrating samples
- G01N1/4077—Concentrating samples by other techniques involving separation of suspended solids
- G01N2001/4088—Concentrating samples by other techniques involving separation of suspended solids filtration
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70589—CD45
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7023—(Hyper)proliferation
- G01N2800/7028—Cancer
Abstract
The invention provides a method for recognizing a peripheral blood circulating tumor cell (CTC) of a tumor
patient based on isolation by size of epithelial tumor cells (ISET), wherein a cell immunochemical method is
used to detect whether CD45 and CD31 on the suspected CTC are expressed or not so as to exclude a
leukocyte and an endothelial cell.
- 1/3
DRAWINGS
12 13
1A 3
FIG. 1
6
77
FIG. 2
Description
- 1/3
12 13
3 1A
FIG. 1
6
77
FIG. 2
[01] The present disclosure relates to a method for recognizing a peripheral blood circulating tumor cell (CTC) of a tumor patient based on isolation by size of epithelial tumor cells (ISET), in particular for recognizing the CTC which is quite difficult to be captured by a physical method and recognized by cell morphology. The present disclosure uses a CD45 and CD31 cell immunochemical method for detection, and belongs to the technical field of molecular biology.
[02] A CTCBIOPSY© detection system separates circulating tumor cells (CTCs) based on a cell size and uses a Wright-Giemsa staining method to stain cells on a filter membrane. The cells detected by the method in strict accordance with SOP operation requirements can be divided into the following categories: CTCs, blood cells, heteromorphic cells and naked nuclear cells. According to cell morphology standards, typical CTCs, blood cells, endothelial cells and naked nuclear cells can be distinguished. However, the heteromorphic cells and suspected CTCs found during a detection process are difficult to be recognized by using a CTC morphology criteria (Hoffman criteria). It is extremely difficult to tell whether such cells are CTCs or other abnormal cells. A method for recognizing the cells is urgently needed.
[03] A CD45 molecule is expressed on all leukocytes and called leukocyte common antigen (LCA). The CD45 molecule is highly expressed in lymphocytes and all other hematopoietic cells except red blood cells and platelets (>106 molecules/cell).
[04] CD31 is also known as a platelet endothelial cell adhesion molecule- (PECAM-1/CD31) and has a molecular weight of 130 kDa. The CD31 structurally belongs to a member of the immunoglobulin superfamily. The CD31 is important for eliminating aged neutrophils in the body. The CD31 is found on surfaces of platelets, neutrophils, monocytes and certain T cells, and tight junctions between endothelial cells. In immunohistochemistry, the CD31 is mainly used to prove an existence of endothelial cell tissues and to assess tumor angiogenesis, which may mean a rapid growing extent of tumors. Malignant vascular endothelial cells usually also retain antigens, so that the CD31 immunohistochemical method can also be used to prove hemangioma and angiosarcoma. It is proved that the CD31 also exists in small lymphocytes and lymphocytic lymphomas, but is not their specific marker molecule. In the prior art, there is no related reports on identifying circulating tumor cells in peripheral blood of tumor patients based on isolation by size of epithelial tumor cells (ISET).
[05] A circulating tumor cell (CTC) falls off from a solid tumor and enters a peripheral blood circulation. Since it was found in 1989, there have been a variety of methods for detecting the CTC in peripheral blood. Recent studies have shown that the detection of the CTC is important for evaluating prognosis of tumor patients, especially patients with advanced cancers, and selecting appropriate personalized treatment. Since the CTC detection is minimally invasive and real-time, it is called a "liquid biopsy" of tumors.
[06] In order to relatively accurately recognize the CTC detected by a CTCBIOPSY© detection system based on isolation by size of epithelial tumor cells (ISET), the present disclosure provides a recognizing method by using a cell immunochemical technology to detect whether CD45 and CD31 on the suspected CTC are expressed or not so as to exclude a leukocyte and an endothelial cell.
[07] To achieve the above objective, the technical solution of the present disclosure is as follows:
[08] The present disclosure provides a method for recognizing a peripheral blood circulating tumor cell (CTC) of a tumor patient based on isolation by size of epithelial tumor cells (ISET), where a cell immunochemical method is used to detect whether CD45 and CD31 on the suspected CTC are expressed or not so as to exclude a leukocyte and an endothelial cell.
[09] Further, the method may specifically include the following steps:
[10] (1) collecting peripheral blood of patients with middle and advanced cancers: collecting 5 ml of peripheral blood from a median cubital vein;
[11] (2) pretreating a peripheral blood sample: adding the collected peripheral blood sample to a diluent for a 10-fold dilution and adding paraformaldehyde to fix the peripheral blood sample for 10 min after the dilution with a final fixing concentration of 0.25%;
[12] (3) filtering the peripheral blood sample by using a device for separating a tumor cell via a membrane filtration to separate and obtain the peripheral blood CTC: adding the pretreated peripheral blood sample to a blood sample container of the device for separating a tumor cell via a membrane filtration and conducting natural filtering by gravity;
[13] (4) after the filtration, taking out a filter from the device for separating a tumor cell by a membrane filtration, adding 0.5 ml of a staining solution A for a CTC to the filter, and conducting staining for 3 min and rinsing with a PBS buffer; after a filtrate isfiltered completely, adding 1 ml of a solution B, conducting staining for 2 min and rinsing with 1 ml of pure water twice, taking out a filter membrane and placing on a glass slide, and conducting observation under a microscope after drying to determine whether the CTC exists; and
[14] (5) detecting expressions of the CD45 and CD31 on the CTC by using the cell immunochemicaltechnology.
[15] Further, the diluent may be composed of 1 mmol/L of EDTA+0.1% of BSA+0.1% of trehalose+0.2% of a polyoxyethylene-polyoxypropylene ether block copolymer and a base solution may be a Tris-HCl buffer.
[16] Further, the staining solution A may be a diaminobenzidine (DAB) staining solution; and the staining solution B may be a hematoxylin staining solution.
[17] Specific processes of the cell immunochemical technology for detecting the expressions of the CD45 and CD31 on the CTC are as follows:
[18] (1) decolorization: taking out a filter membrane with the CTC from the glass slide, soaking the CTC in a decolorization solution for 4-6 h, and removing the CTC staining solution;
[19] (2) adding 100 1 of 0.1% of Triton X-100 dropwise and conducting incubation at room temperature for 15 min and washing with deionized (DI) water for 3 times with 2 min for each time;
[20] (3) adding 100 1 of 0.3% of H202 dropwise and conducting incubation at room temperature for 10 min and washing with PBS for 3 times with 2 min for each time;
[21] (4) adding 100 1 of CD45 (human) and CD31 (human) primary antibodies dropwise and conducting incubation at room temperature for 2 h (or overnight at 4C) and washing with PBS for 3 times with 2 min for each time;
[22] (5) adding 100 1 of goat anti-human IgG/HRP dropwise and conducting incubation at room temperature for 20 min and washing with PBS for 3 times with 2 min for each time;
[23] (6) adding 100 1 of a diaminobenzidine (DAB) color developing solution, conducting incubation at room temperature and observing color development under a microscope at any time;
[24] (7) after the color development is completed, discarding the DAB color development solution and conducting rinsing with running water for 5 min and staining with hematoxylin for 5 min;
[25] (8) conducting differentiation with hydrochloric acid and alcohol for 8 s and blue turning with tap water for 5 min;
[26] (9) conducting a gradient ethanol dehydration with 75% ethanol (1 min), 95% ethanol (1 min) and 100% ethanol (1 min), air-drying, and sealing with neutral resin; and
[27] (10) conducting a microscopic examination under an optical microscope.
[28] Further, the decolorization solution may be prepared by evenly mixing 95% alcohol and 100% xylene in a volume ratio of 1:1.
[29] A device for separating a tumor cell by a membrane filtration used in the present disclosure includes a filter, a blood sample container, a waste liquid tank, and an iron stand. The iron stand is provided with a base, a vertical stand and a bracket. The blood sample container is arranged on an upper part of the iron stand through the bracket. The filter is arranged below the blood sample container and connected to the waste liquid tank through an infusion apparatus. The waste liquid tank is arranged on the base.
[30] The filter includes a filter upper mouth, a filter membrane, a filter membrane carrier platform and a filter lower mouth. The filter membrane is placed on the filter membrane carrier platform. The filter upper mouth is connected to the blood sample container and the filter lower mouth is connected to the waste liquid tank through the infusion apparatus.
[31] The filter membrane is made of a hydrophobic material and filter holes with a diameter of 8 mm are evenly distributed in thefilter membrane.
[32] The filter membrane obtained by a CTCBIOPSY@ detection system is stained, CTC and suspected CTC and heteromorphic cells identified by cell morphology are observed and imaged, immunocytochemical staining of common antigens CD45 and CD31 on surfaces of leukocytes is used to distinguish the CTC and hematogenous and endothelial cells so as to reduce a false positive rate of the CTCBIOPSY@ in detecting the CTC. The method improves specificity, more accurately detects the CTC and has important clinical guidance significance in evaluating an illness state and a curative effect by clinically applying CTC detection.
[33] The present disclosure has the following beneficial effects:
[34] (1) The detection method can accurately recognize the CTC in peripheral blood of tumor patients, belongs to the field of minimally invasive technologies and can be used for real-time dynamic detection.
[35] (2) The method provided by the present disclosure can more accurately detect the CTC, reduces a false positive rate of CTC detection, and improves specificity. The method has important clinical guidance significance in evaluating an illness state and a curative effect by clinically applying CTC detection.
[36] FIG. 1 is a structural schematic diagram of a membrane filtration device of the present disclosure;
[37] FIG. 2 is a structural schematic section diagram of a filter of a membrane filtration device of the present disclosure;
[38] FIG. 3 is a structural schematic diagram of a filter membrane of a filter of a membrane filtration device of the present disclosure;
[39] FIG. 4 is an image of a circulating tumor cell separated and obtained from peripheral blood of a patient with a liver cancer (A) and a staining image of CD45 and CD31 in a circulating tumor cell in peripheral blood (B);
[40] FIG. 5 is an image of a circulating tumor cell separated and obtained from peripheral blood of a patient with a kidney cancer (A) and a staining image of CD45 and CD31 in a circulating tumor cell in peripheral blood (B);
[41] FIG. 6 is an image of a circulating tumor cell separated and obtained from peripheral blood of a patient with a lung cancer (A) and a staining image of CD45 and CD31 in a circulating tumor cell in peripheral blood (B); and
[42] FIG. 7 shows criteria on combination of an image of a circulating tumor cell and immunohistochemistry.
[43] Reference numerals: 1 iron stand, 2 blood sample container, 3 filter, 4 infusion apparatus, 5 waste liquid tank, 6 filter upper mouth, 7 filter membrane, 8 filter membrane carrier platform, 9 filter lower mouth, 10 filter hole, 11 base, 12 vertical stand and 13 bracket.
[44] The present disclosure will be described in combination with the drawings and embodiments.
[45] Examples by using the method to separate, obtain and identify a circulating tumor cell in peripheral blood of 8 cases of tumor patients (8 cases of normal human samples are detected at the same time as a negative control) are as follows.
[46] 1. Separation and obtaining of CTC in peripheral blood of patients with middle and advanced tumors by using membrane filtration device
[47] Five milliliter of fasting blood was collected from a median cubital vein after subjects fasted for 8-12 h, the peripheral blood was diluted by using 45 ml of a diluent (components are 1 mmol/L of EDTA+0.1% of BSA+0.1% of trehalose+0.2% of a polyoxyethylene-polyoxypropylene ether block copolymer and a base solution is a Tris-HCl buffer), and 3 ml of 4% of paraformaldehyde was added to fix the diluted blood sample for 10 min;
[48] in a fixing period, a membrane filtration device is assembled: as shown in FIGs. 1, 2, and 3, the filtration device is composed of a filter 3, a filter membrane 7, a blood sample container 2, a waste liquid tank 5, and an iron stand 1;
[49] 10 ml of PBS was used to wet thefilter 3, thefixed peripheral blood sample was added to the blood sample container 2 of the membrane filtration device to be filtered naturally by gravity, and a circulating tumor cell (CTC) was trapped on the filter membrane 7;
[50] where, a diameter of a tumor cell is generally greater than 15 microns, while a diameter of a blood cell (including a red blood cell and a leukocyte) is generally less than 8 microns, so that after the peripheral blood containing the CTC was filtered, the blood cell can be filtered out since the diameter of the blood cell is smaller than that of filter holes 10, while the CTC was trapped on the filter membrane 7 since the diameter of the CTC is larger than that of the filter holes 10;
[51] after the filtration, the filter 3 was taken from the filtration device and opened, a filter upper mouth 6 was removed, 0.5 ml of a staining solution A for the CTC was added to the filter, staining was conducted for 3 min, and the filter 3 was rinsed clean with PBS buffer; after a filtrate was filtered completely, 1 ml of a solution B was added, staining was conducted for 2 min, the filter 3 was rinsed clean with 1 ml of pure water and PBS buffer, and the filter membrane 7 was taken out with ophthalmic tweezers and placed on a glass slide with a cell face facing upward; and
[52] observation was conducted under a microscope after the filter membrane was dried to determine whether the CTC existed.
[53] Through observation, no CTC was found in 8 healthy volunteers. Except 1 case of a tumor patient, the CTC was detected in the other 7 cases of tumor patients. Expressions of CD45 and CD31 were negative in all cases (Table 1). A positive rate of the detection was 87.5%.
[54] Table 1 Detection result of CTC in an example Detection Result (number of Sample NO. Sample Source CTC) 1 Healthy volunteer 0 2 Healthy volunteer 0 3 Healthy volunteer 0 4 Healthy volunteer 0 5 Healthy volunteer 0 6 Healthy volunteer 0 7 Healthy volunteer 0 8 Healthy volunteer 0 9 Patient with advanced liver cancer 2 10 Patient with advanced gastric cancer 1 11 Patient with advanced colon cancer 3 12 Patient with middle kidney cancer 1 13 Patient with middle lung cancer 0 14 Patient with advanced esophagus cancer 5 15 Patient with middle gastric cancer 1 16 Patient with advanced liver cancer 2
[55] 2. Detection of expressions of CD45 and CD31 on CTC by using cell immunochemical technology
[56] A filter membrane 7 with CTC was taken from a glass slide, the CTC was soaked in a decolorization solution prepared by evenly mixing 95% of ethanol and 100% of xylene at a volume ratio of 1:1 for 4-6 h, and the CTC staining solution was removed; 100 l of 0.1% of Triton X-100 was added dropwise, incubation was conducted at room temperature for 15 min, and washing was conducted with deionized (DI) water for 3 times with 2 min for each time; 100 1 of 0.3% of H202 was added dropwise, incubation was conducted at room temperature for 10 min and washing was conducted with PBS for 3 times with 2 min for each time; 100 [ of CD45 (human) and CD31 (human) primary antibodies were added dropwise, incubation was conducted at room temperature for 2 h (or overnight at 4C) and washing was conducted with PBS for 3 times with 2 min for each time; 100 [ of goat anti-human IgG/HRP was added dropwise, incubation was conducted at room temperature (18-26°C) for 20 min and a developing condition was observed under a microscope at any time (generally 3-10 min and no more than 10 min); after the color development, a diaminobenzidine (DAB) color development solution was discarded, rinsing was conducted with running water for 5 min and staining was conducted with hematoxylin for 5 min; differentiation was conducted with hydrochloric acid and alcohol for 8 s and blue turning was conducted with tap water for 5 min; a gradient ethanol dehydration with 75% ethanol (1 min), 95% ethanol (1 min) and 100% ethanol (1 min), air-drying, and sealing with neutral resin were conducted; and a microscopic examination was conducted under an optical microscope, and films were read by cytopathologists and expressions of CD45 and CD31 were determined according to a degree of cell membrane staining. Immunocytochemical staining of common antigens CD45 and CD31 on surfaces of leukocytes was used to distinguish the CTC and hematogenous and endothelial cells so as to reduce a false positive rate of a CTCBIOPSY© in detecting the CTC. The method improves specificity, more accurately detects the CTC and has important clinical guidance significance in evaluating an illness state and a curative effect by clinically applying CTC detection.
[57] In FIGs. 4-6, A represented an image of a circulating tumor cell separated and obtained from peripheral blood of a tumor patient, a cell nucleus was atypia, a nucleo-cytoplasmic ratio was greater than 0.8, a diameter of the cell is larger than 15 m, the nucleus was deeply and unevenly stained, or the cell and chromatin shifted, or abnormal mitosis existed, and positive CTC was determined; B represented an immunocytochemical staining of CD45 and CD31, where, if a brown yellow appeared around a cell membrane, it was determined to be positive and CTC was excluded according to criteria of immunohistochemistry; and the specific criteria were shown in FIG. 7.
Claims (5)
- WHAT IS CLAIMED IS: 1. A method for recognizing a peripheral blood circulating tumor cell (CTC) of a tumor patient based on isolation by size of epithelial tumor cells (ISET), wherein a cell immunochemical method is used to detect whether CD45 and CD31 on the suspected CTC are expressed or not so as to exclude a leukocyte and an endothelial cell.
- 2. The preparation method according to claim 1, specifically comprising the following steps: (1) collecting peripheral blood of patients with middle and advanced cancers: collecting 5 ml of peripheral blood from a median cubital vein; (2) pretreating a peripheral blood sample: adding the collected peripheral blood sample to a diluent for a 10-fold dilution and adding paraformaldehyde to fix the peripheral blood sample for 10 min after the dilution with a final fixing concentration of 0.25%; (3) filtering the peripheral blood sample by using a device for separating a tumor cell via a membrane filtration to separate and obtain the peripheral blood CTC: adding the pretreated peripheral blood sample to a blood sample container of the device for separating a tumor cell via a membrane filtration and conducting natural filtering by gravity; (4) after the filtration, taking out a filter from the device for separating a tumor cell by a membrane filtration, adding 0.5 ml of a staining solution A for a CTC to the filter, and conducting staining for 3 min and rinsing with a PBS buffer; after a filtrate isfiltered completely, adding 1 ml of a solution B, conducting staining for 2 min and rinsing with 1 ml of pure water twice, taking out a filter membrane and placing on a glass slide, and conducting observation under a microscope after drying to determine whether the CTC exists; and (5) detecting expressions of the CD45 and CD31 on the CTC by using the cell immunochemicaltechnology.
- 3. The method according to claim 2, wherein the diluent is composed of 1 mmol/L of EDTA+0.1% of BSA+0.1% of trehalose+0.2% of a polyoxyethylene-polyoxypropylene ether block copolymer and a base solution is a Tris-HCl buffer.
- 4. The method according to claim 2, wherein the staining solution A is a diaminobenzidine (DAB) staining solution; and the staining solution B is a hematoxylin staining solution.
- 5. The method according to any one of claims 2-4, wherein specific processes of the cell immunochemical technology for detecting the expressions of the CD45 and CD31 on the CTC are as follows:(1) decolorization: taking out a filter membrane with the CTC from the glass slide, soaking the CTC in a decolorization solution for 4-6 h, and removing the CTC staining solution; (2) adding 100 1 of 0.1% of Triton X-100 dropwise and conducting incubation at room temperature for 15 min and washing with deionized (DI) water for 3 times with 2 min for each time; (3) adding 100 1 of 0.3% of H202 dropwise and conducting incubation at room temperature for 10 min and washing with PBS for 3 times with 2 min for each time; (4) adding 100 1 of CD45 (human) and CD31 (human) primary antibodies dropwise and conducting incubation at room temperature for 2 h (or overnight at 4C) and washing with PBS for 3 times with 2 min for each time; (5) adding 100 1 of goat anti-human IgG/HRP dropwise and conducting incubation at room temperature for 20 min and washing with PBS for 3 times with 2 min for each time; (6) adding 100 1 of a diaminobenzidine (DAB) color developing solution, conducting incubation at room temperature and observing color development under a microscope at any time; (7) after the color development is completed, discarding the DAB color development solution and conducting rinsing with running water for 5 min and staining with hematoxylin for 5 min; (8) conducting differentiation with hydrochloric acid and alcohol for 8 s and blue turning with tap water for 5 min; (9) conducting a gradient ethanol dehydration with 75% ethanol (1 min), 95% ethanol (1 min) and 100% ethanol (1 min), air-drying, and sealing with neutral resin; and (10) conducting a microscopic examination under an optical microscope; wherein the decolorization solution is prepared by evenly mixing 95% alcohol and 100% xylene in a volume ratio of 1:1.-1/3-DRAWINGS Jun 2021 2021103347FIG. 1FIG. 2-2/3- Jun 2021 2021103347FIG. 3FIG. 4FIG. 5-3/3- Jun 2021 2021103347FIG. 6Conclusion: final determination is primary based on an optical result and an immunohistochemical result is considered. CTC CTC positive CTC negative suspected (optical) (optical) (optical)immunohistochemical immunohistochemical immunohistochemical marker CD45& CD31 marker CD45& CD31 marker CD45& CD31Positive Negative Positive Negative Positive NegativeCTC Other cells Suspecte Excluded Excluded not derived Excluded positive d from blood & endothelial cellsFIG. 7
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2021103347A AU2021103347A4 (en) | 2021-06-15 | 2021-06-15 | Method for recognizing peripheral blood circulating tumor cell of tumor patient based on isolation by size of epithelial tumor cells |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2021103347A AU2021103347A4 (en) | 2021-06-15 | 2021-06-15 | Method for recognizing peripheral blood circulating tumor cell of tumor patient based on isolation by size of epithelial tumor cells |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2021103347A4 true AU2021103347A4 (en) | 2021-08-05 |
Family
ID=77076060
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2021103347A Ceased AU2021103347A4 (en) | 2021-06-15 | 2021-06-15 | Method for recognizing peripheral blood circulating tumor cell of tumor patient based on isolation by size of epithelial tumor cells |
Country Status (1)
Country | Link |
---|---|
AU (1) | AU2021103347A4 (en) |
-
2021
- 2021-06-15 AU AU2021103347A patent/AU2021103347A4/en not_active Ceased
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2021213323A1 (en) | Non-diagnostic method for detecting pd-l1 gene mutation of patient with colorectal cancer by means of circulating tumor cells in peripheral blood | |
WO2022001824A1 (en) | Kit and method for detecting pd-l1 gene mutations in circulating tumor cells in peripheral blood of patient with small cell lung cancer | |
CN111562375B (en) | Immunofluorescence kit for detecting expression of peripheral blood circulating tumor cells PD-L1 of gastric cancer patient and detection method | |
CN111638357A (en) | Immunofluorescence kit and method for E-Cadherin mutation of peripheral blood circulating tumor cells of patient with non-small cell lung cancer | |
CN111638359A (en) | Immunofluorescence kit and detection method for detecting PD-L1 gene mutation of peripheral blood circulating tumor cells of small cell lung cancer patients | |
CN111521796A (en) | Immunofluorescence kit and detection method for detecting expression of peripheral blood circulating tumor cells PD-L1 of renal cancer patient | |
CN111521798A (en) | Kit and method for detecting PD-L1 gene mutation of peripheral blood circulating tumor cells of renal cancer patients | |
CN111521794A (en) | Immunofluorescence kit and detection method for detecting NSE gene mutation of peripheral blood circulating tumor cells of small cell lung cancer patients | |
AU2021103347A4 (en) | Method for recognizing peripheral blood circulating tumor cell of tumor patient based on isolation by size of epithelial tumor cells | |
CN111679077A (en) | Immunofluorescence kit for expressing E-Cadherin (circulating tumor cell) in peripheral blood of renal cell carcinoma patient and detection method | |
CN111521793A (en) | Immunofluorescence kit and detection method for detecting CEA gene mutation of peripheral blood circulating tumor cells of non-small cell lung cancer patients | |
CN111638358A (en) | Immunofluorescence kit and method for E-Cadherin mutation of peripheral blood circulating tumor cells of small cell lung cancer patients | |
CN111562377A (en) | Kit and method for detecting expression of peripheral blood circulating tumor cells CA199 of pancreatic cancer patient | |
CN111521791A (en) | Kit and method for detecting NSE gene mutation of peripheral blood circulating tumor cells of small cell lung cancer patients | |
CN111812324A (en) | Method for detecting lung cancer circulating tumor cells | |
CN111521795A (en) | Kit and method for detecting non-small cell lung cancer patient peripheral blood circulating tumor cell PD-L1 gene mutation | |
CN111638354A (en) | Immunofluorescence kit for detecting expression of peripheral blood circulating tumor cells E-Cadherin of pancreatic cancer patient | |
CN111521789A (en) | Immunofluorescence kit and detection method for detecting expression of peripheral blood circulating tumor cells CA199 of pancreatic cancer patient | |
CN111856022A (en) | Kit and method for detecting expression of peripheral blood circulating tumor cells E-Cadherin of pancreatic cancer patient | |
CN111638338A (en) | Method for detecting E-Cadherin expression of colorectal cancer patient through peripheral blood circulating tumor cells | |
CN111610334A (en) | Method for identifying peripheral blood circulation tumor cells of tumor patient based on cell size filtration | |
CN111638345A (en) | Kit and method for detecting E-Cadherin gene mutation of peripheral blood circulating tumor cells of patient with non-small cell lung cancer | |
CN111551719A (en) | Kit and method for detecting expression of peripheral blood circulating tumor cells PD-L1 of pancreatic cancer patient | |
CN111534586A (en) | Kit and method for detecting CEA gene mutation of peripheral blood circulating tumor cells of non-small cell lung cancer patients | |
CN111638344A (en) | Kit and method for detecting E-Cadherin gene mutation of peripheral blood circulating tumor cells of small cell lung cancer patients |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FGI | Letters patent sealed or granted (innovation patent) | ||
MK22 | Patent ceased section 143a(d), or expired - non payment of renewal fee or expiry |